MA37645B1 - Formulations stabilisées contenant des anticorps anti-dll4 - Google Patents
Formulations stabilisées contenant des anticorps anti-dll4Info
- Publication number
- MA37645B1 MA37645B1 MA37645A MA37645A MA37645B1 MA 37645 B1 MA37645 B1 MA 37645B1 MA 37645 A MA37645 A MA 37645A MA 37645 A MA37645 A MA 37645A MA 37645 B1 MA37645 B1 MA 37645B1
- Authority
- MA
- Morocco
- Prior art keywords
- formulations containing
- containing anti
- antibody
- dll4 antibodies
- stabilized formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000006184 cosolvent Substances 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000008646 thermal stress Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
La présente invention concerne des formulations pharmaceutiques comprenant un anticorps qui se lie spécifiquement à un ligand humain delta-like 4 (dll4). Lesdites formulations peuvent contenir, outre un anticorps anti-dll4, un tampon de phosphate, un co-solvant organique, un disaccharide, et un sel. Les formulations pharmaceutiques selon la présente invention présentent un degré substantiel de stabilité d'anticorps après stockage pendant plusieurs mois et après avoir été soumises à une contrainte thermique et à d'autres contraintes physiques.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653478P | 2012-05-31 | 2012-05-31 | |
| PCT/US2013/043516 WO2013181486A1 (fr) | 2012-05-31 | 2013-05-31 | Formulations stabilisées contenant des anticorps anti-dll4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MA37645A2 MA37645A2 (fr) | 2016-08-31 |
| MA37645A3 MA37645A3 (fr) | 2017-07-31 |
| MA37645B1 true MA37645B1 (fr) | 2018-10-31 |
Family
ID=48670784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37645A MA37645B1 (fr) | 2012-05-31 | 2013-05-31 | Formulations stabilisées contenant des anticorps anti-dll4 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9675692B2 (fr) |
| EP (1) | EP2854849B1 (fr) |
| JP (1) | JP6144758B2 (fr) |
| KR (1) | KR20150033615A (fr) |
| CN (1) | CN104349791A (fr) |
| AR (1) | AR092325A1 (fr) |
| AU (1) | AU2013267301B2 (fr) |
| BR (1) | BR112014028997A2 (fr) |
| CA (1) | CA2872275C (fr) |
| CL (1) | CL2014003237A1 (fr) |
| CO (1) | CO7151478A2 (fr) |
| DK (1) | DK2854849T3 (fr) |
| EA (1) | EA029779B1 (fr) |
| ES (1) | ES2668900T3 (fr) |
| HK (1) | HK1207305A1 (fr) |
| IL (1) | IL235468A0 (fr) |
| LT (1) | LT2854849T (fr) |
| MA (1) | MA37645B1 (fr) |
| MX (1) | MX357146B (fr) |
| NO (1) | NO2887943T3 (fr) |
| NZ (1) | NZ702288A (fr) |
| PH (1) | PH12014502429B1 (fr) |
| PL (1) | PL2854849T3 (fr) |
| PT (1) | PT2854849T (fr) |
| SG (1) | SG11201407171XA (fr) |
| SI (1) | SI2854849T1 (fr) |
| SM (1) | SMT201800216T1 (fr) |
| TW (1) | TWI609696B (fr) |
| UY (1) | UY34842A (fr) |
| WO (1) | WO2013181486A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3485908B1 (fr) | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Combinaison thérapeutique et utilisation d'anticorps antagonistes de dll4 et d'agents anti-hypertenseurs |
| TWI583699B (zh) | 2011-09-23 | 2017-05-21 | 安可美德藥物股份有限公司 | Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途 |
| EP3212233B1 (fr) | 2014-10-31 | 2020-06-24 | Oncomed Pharmaceuticals, Inc. | Thérapie combinée pour le traitement d'une maladie |
| US20180200325A1 (en) * | 2014-11-18 | 2018-07-19 | Shionogi & Co., Ltd. | Stabilized peptide composition |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| CA3097058A1 (fr) * | 2018-04-16 | 2019-10-24 | Merck Patent Gmbh | Additifs pour formulations proteiques en vue d'ameliorer la stabilite thermique |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| CA3185091A1 (fr) * | 2020-07-08 | 2022-01-13 | Yuan Cheng | Formulations stabilisees contenant des anticorps anti-ctla-4 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| US5016784A (en) | 1990-02-15 | 1991-05-21 | Dexus Research Inc. | Applicator for highly reactive materials |
| AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0852951A1 (fr) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ATE230277T1 (de) | 1997-06-13 | 2003-01-15 | Genentech Inc | Stabilisierte antikörperformulierung |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
| DE60139944D1 (de) | 2000-10-12 | 2009-10-29 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| ATE454137T1 (de) | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| WO2003068260A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| PT1610820E (pt) | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| WO2005072772A1 (fr) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Compositions pharmaceutiques |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA3142945A1 (fr) | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Formulations a tampon d'histidine d'antagoniste du vegf |
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| CA2654510C (fr) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Formulations antagonistes du vegf appropriees a une administration intravitreenne |
| WO2008049897A1 (fr) | 2006-10-27 | 2008-05-02 | Ablynx N.V. | Administration intranasale de polypeptides et de protéines |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| PE20120359A1 (es) | 2009-03-06 | 2012-04-13 | Genentech Inc | Formulacion con anticuerpo |
| EP3485908B1 (fr) * | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Combinaison thérapeutique et utilisation d'anticorps antagonistes de dll4 et d'agents anti-hypertenseurs |
| PL3721904T3 (pl) | 2009-11-20 | 2022-01-31 | Biocon Limited | Formulacje przeciwciała t1h |
| WO2011109298A2 (fr) * | 2010-03-02 | 2011-09-09 | Abbott Laboratories | Protéines thérapeutiques de liaison à dll4 |
| MX366337B (es) * | 2010-10-06 | 2019-07-05 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
-
2013
- 2013-05-29 AR ARP130101868A patent/AR092325A1/es unknown
- 2013-05-30 TW TW102119047A patent/TWI609696B/zh not_active IP Right Cessation
- 2013-05-31 ES ES13730702.1T patent/ES2668900T3/es active Active
- 2013-05-31 AU AU2013267301A patent/AU2013267301B2/en active Active
- 2013-05-31 MA MA37645A patent/MA37645B1/fr unknown
- 2013-05-31 CA CA2872275A patent/CA2872275C/fr active Active
- 2013-05-31 NZ NZ702288A patent/NZ702288A/en not_active IP Right Cessation
- 2013-05-31 MX MX2014014363A patent/MX357146B/es active IP Right Grant
- 2013-05-31 WO PCT/US2013/043516 patent/WO2013181486A1/fr not_active Ceased
- 2013-05-31 CN CN201380028578.1A patent/CN104349791A/zh active Pending
- 2013-05-31 PL PL13730702T patent/PL2854849T3/pl unknown
- 2013-05-31 EA EA201492186A patent/EA029779B1/ru not_active IP Right Cessation
- 2013-05-31 HK HK15108004.0A patent/HK1207305A1/xx unknown
- 2013-05-31 EP EP13730702.1A patent/EP2854849B1/fr active Active
- 2013-05-31 US US13/906,479 patent/US9675692B2/en active Active
- 2013-05-31 KR KR1020147035879A patent/KR20150033615A/ko not_active Withdrawn
- 2013-05-31 SI SI201330979T patent/SI2854849T1/en unknown
- 2013-05-31 SG SG11201407171XA patent/SG11201407171XA/en unknown
- 2013-05-31 UY UY0001034842A patent/UY34842A/es unknown
- 2013-05-31 PT PT137307021T patent/PT2854849T/pt unknown
- 2013-05-31 LT LTEP13730702.1T patent/LT2854849T/lt unknown
- 2013-05-31 DK DK13730702.1T patent/DK2854849T3/en active
- 2013-05-31 BR BR112014028997A patent/BR112014028997A2/pt not_active IP Right Cessation
- 2013-05-31 SM SM20180216T patent/SMT201800216T1/it unknown
- 2013-05-31 JP JP2015515218A patent/JP6144758B2/ja active Active
- 2013-08-23 NO NO13831626A patent/NO2887943T3/no unknown
-
2014
- 2014-10-29 PH PH12014502429A patent/PH12014502429B1/en unknown
- 2014-11-03 IL IL235468A patent/IL235468A0/en unknown
- 2014-11-27 CL CL2014003237A patent/CL2014003237A1/es unknown
- 2014-12-23 CO CO14281503A patent/CO7151478A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37645A3 (fr) | Formulations stabilisées contenant des anticorps anti-dll4 | |
| MA35904B1 (fr) | Formulations stabilisées contenant des anticorps anti-ang2 | |
| Yewdell et al. | Original antigenic sin: how original? How sinful? | |
| MA33993B1 (fr) | Formulations stabilisées contenant des anticorps contre le récepteur de l'interleukine-6 (il-6r) | |
| MA35355B1 (fr) | Formulations stabilisées contenant des anticorps anti-pcsk9 | |
| AR130402A2 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| EP3941945A4 (fr) | Anticorps dirigés contre l'antigène trophoblaste 2 de surface cellulaire (trop2) et conjugués anticorps-médicament les comprenant | |
| SG11201907321TA (en) | Anti-gprc5d antibody and molecule comprising the antibody | |
| TNSN07304A1 (en) | Combination of xolair with immunosuppressive agent | |
| JO3449B1 (ar) | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب | |
| JP2007520566A5 (fr) | ||
| PH12013500672A1 (en) | Stabilized formulations containing anti-interleukin-4-receptor (il-4r) antibodies | |
| MA62173B1 (fr) | Formulations d'anticorps anti-rankl humains et leurs procédés d'utilisation | |
| CY1113003T1 (el) | Ευσταθη παρασκευασματα laquinimod | |
| FR18C1032I2 (fr) | Anticorps anti-fgf23 et composition pharmaceutique le comprenant | |
| EP2471814A4 (fr) | Anticorps monoclonal anti-vegf et composition pharmaceutique comprenant ledit anticorps | |
| IL194550A (en) | Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use | |
| IL214779A (en) | Isolated monoclonal antibody or epitope-binding antibody on cadm1, methods of preparation and use for drug preparation | |
| MA34541B1 (fr) | Compositions d'anticorps et procédés d'utilisation | |
| EP3983446A4 (fr) | Anticorps anti-epcam conditionnellement actifs, fragments d'anticorps, leurs immunoconjugués et utilisations associées | |
| PH12021552092A1 (en) | Stabilized formulations containing anti-il-33 antibodies | |
| Corral et al. | Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis | |
| EA201070826A1 (ru) | Антитела против pcrv | |
| UA109148C2 (uk) | Композиції на основі антитіла проти vegfr-3 | |
| TR201007250A2 (tr) | Selobioz içeren formülasyon. |